Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday. Shares of Moderna ...

Moderna (MRNA) has disclosed a new risk, in the Sales & Marketing category. Moderna faces significant commercial challenges, particularly in ...

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

Bullish option flow detected in Moderna (MRNA) with 76,253 calls trading, 1.4x expected, and implied vol increasing almost 8 points to 77.82%.

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against firms that kick off shortened trading week with impressive gains. The stock market kicked off the ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.

Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...